Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Oprah Winfrey is sparking a debate around weight, willpower and perception after the media mogul revealed her perceptions about “thin people” and what she called “food noise” while discussing taking a ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Oprah Winfrey reflects on past misconceptions about weight, admitting that a GLP-1 drug shifted her perspective.

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.